Comparison
CJC-1295 vs. Lixisenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
no data
320367-13-3
Molecular weight
3647.3 g/mol
4858.5 g/mol
Half-life
144 h
3 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
5
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
3
1